- Home
- RFL vs BRNS Comparison
RFL vs BRNS Comparison
Compare RFL & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFL | BRNS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 24.1M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RFL | BRNS |
|---|---|---|
| Price | $1.33 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 68.3K | 21.2K |
| Earning Date | 06-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $0.51 |
| 52 Week High | $3.19 | $2.91 |
Technical Indicators
Market Signals| Indicator | RFL | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 56.66 |
| Support Level | $1.30 | $0.66 |
| Resistance Level | $1.38 | $0.75 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 61.11 | 57.43 |
Price Performance
Historical ComparisonAbout RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.